INSM

Company Overview — What Does INSMED Inc Do?

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey. INSMED Inc (INSM) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO William H. Lewis and employs approximately 740 people, headquartered in BRIDGEWATER, New Jersey. With a market capitalization of $35.5B, INSM is one of the prominent companies in the Healthcare sector.

INSMED Inc (INSM) Stock Rating — Hold (April 2026)

As of April 2026, INSMED Inc receives a Hold rating with a composite score of 41.2/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.INSM ranks #1,075 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, INSMED Inc ranks #76 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

INSM Stock Price and 52-Week Range

INSMED Inc (INSM) currently trades at $154.81. The stock lost $4.78 (3.0%) in the most recent trading session. The 52-week high for INSM is $212.75, which means the stock is currently trading -27.2% from its annual peak. The 52-week low is $60.40, putting the stock 156.3% above its annual trough. Recent trading volume was 1.8M shares, reflecting moderate market activity.

Is INSM Overvalued or Undervalued? — Valuation Analysis

INSMED Inc (INSM) carries a value factor score of 30/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 47.62x, versus the sector average of 2.75x. The price-to-sales ratio is 80.71x, compared to 1.66x for the average Healthcare stock.

At current multiples, INSMED Inc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

INSMED Inc Profitability — ROE, Margins, and Quality Score

INSMED Inc (INSM) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -158.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -51.6% versus the sector average of -33.1%.

On a margin basis, INSMED Inc reports gross margins of 76.9%, compared to 71.5% for the sector. The operating margin is -261.0% (sector: -66.1%). Net profit margin stands at -268.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 57.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

INSM Debt, Balance Sheet, and Financial Health

INSMED Inc has a debt-to-equity ratio of 74.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.83x, indicating strong short-term liquidity. Total debt on the balance sheet is $547M. Cash and equivalents stand at $335M.

INSM has a beta of 0.61, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for INSMED Inc is 57/100, reflecting average volatility within the normal range for its sector.

INSMED Inc Revenue and Earnings History — Quarterly Trend

In TTM 2026, INSMED Inc reported revenue of $436M and earnings per share (EPS) of $-6.42. Net income for the quarter was $-1.17B. Gross margin was 76.9%. Operating income came in at $-1.14B.

In FY 2025, INSMED Inc reported revenue of $606M and earnings per share (EPS) of $-6.42. Net income for the quarter was $-1.28B. Gross margin was 79.7%. Revenue grew 66.7% year-over-year compared to FY 2024. Operating income came in at $-1.25B.

In Q3 2025, INSMED Inc reported revenue of $142M and earnings per share (EPS) of $-1.75. Net income for the quarter was $-370M. Gross margin was 79.4%. Revenue grew 52.4% year-over-year compared to Q3 2024. Operating income came in at $-366M.

In Q2 2025, INSMED Inc reported revenue of $107M and earnings per share (EPS) of $-1.70. Net income for the quarter was $-322M. Gross margin was 73.9%. Revenue grew 18.9% year-over-year compared to Q2 2024. Operating income came in at $-313M.

Over the past 8 quarters, INSMED Inc has demonstrated a growth trajectory, with revenue expanding from $90M to $436M. Investors analyzing INSM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

INSM Dividend Yield and Income Analysis

INSMED Inc (INSM) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

INSM Momentum and Technical Analysis Profile

INSMED Inc (INSM) has a momentum factor score of 59/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 66/100 reflects moderate short selling activity.

INSM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, INSMED Inc (INSM) ranks #76 out of 838 stocks based on the Blank Capital composite score. This places INSM in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing INSM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INSM vs S&P 500 (SPY) comparison to assess how INSMED Inc stacks up against the broader market across all factor dimensions.

INSM Next Earnings Date

No upcoming earnings date has been announced for INSMED Inc (INSM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy INSM? — Investment Thesis Summary

INSMED Inc presents a balanced picture with arguments on both sides. The quality score of 25/100 flags below-average profitability. The value score of 30/100 indicates premium valuation.

In summary, INSMED Inc (INSM) earns a Hold rating with a composite score of 41.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INSM stock.

Related Resources for INSM Investors

Explore more research and tools: INSM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare INSM head-to-head with peers: INSM vs AZN, INSM vs SLGL, INSM vs VMD.